Global Continuous Positive Airway Pressure (CPAP) Market Size & Trends Report Segmented by Device Type (Automatic, Fixed Pressure, BiPAP), Modality (Standalone Benchtop Systems, Portable Devices), End-user (Hospitals, Clinics, Home-care Settings) & Regional Forecast to 2031

Continuous Positive Airway Pressure (CPAP) is a medical device used for noninvasive treatment of breathing problems, primarily obstructive sleep apnea (OSA). A CPAP device consists of a machine, a flexible tube, and a mask (covering nose, mouth, or both). The CPAP machine delivers a continuous, mild flow of pressurized air through a mask. This constant air pressure keeps the upper airway open during sleep, preventing airway collapse, snoring, and interrupted breathing. By maintaining an open airway, the device prevents the throat muscles from relaxing too much and blocking airflow. CPAP therapy is considered a first-line treatment for moderate to severe OSA, but also treats central sleep apnea, obesity hypoventilation syndrome, and neuromuscular disorders. Beyond this, CPAP helps in eliminating sleep disruptions, reducing excessive daytime fatigue, thereby lowering the risk of high blood pressure, heart disease, and stroke. Although initially uncomfortable, it is considered the most reliable method for treating sleep apnea.

Rising prevalence and diagnosis of sleep apnea to drive demand

The increasing prevalence of obstructive sleep apnea is a key driver for the CPAP market. This surge in the number of OSA cases is closely linked to lifestyle-related risk factors such as obesity, physical inactivity, smoking, and metabolic disorders. According to an article published by NIH, obstructive sleep apnea (OSA) is an increasingly common disorder, affecting approximately 17% of adult women and 34% of men. Further, as global obesity rates continue to rise, the addressable patient population for CPAP therapy is expanding in both developed and emerging economies.

Another important factor is the improvement in diagnostic rates. Sleep disorders were historically underdiagnosed due to limited access to sleep laboratories and low awareness among primary care physicians. However, with an increasing number of public awareness campaigns like the Count on Sleep, a collaborative multi-organizations project led by the American Academy of Sleep Medicine, is helping to drive this awareness and educating both the public and the healthcare communities on the importance of diagnosis and long-term treatment. This has changed with the broader use of home sleep testing devices and screening tools, which have lowered the threshold for diagnosis. Consequently, earlier and more frequent diagnosis has directly translated into higher prescription volumes for CPAP devices. Moreover, untreated sleep apnea can lead to cardiovascular disease, hypertension, diabetes, and reduced cognitive performance. As these risks are increasingly recognized, physicians are more inclined to initiate CPAP therapy as part of long-term disease management strategies.

To learn more about this report, download the PDF brochure

The rapid shift toward home-based respiratory care propels CPAP market growth

Traditionally, the diagnosis procedure for OSA required patients to stay overnight in a specialized sleep lab, which is an expensive and uncomfortable process called polysomnography. However, there is a rapid shift toward "Home Sleep Apnea Testing" as the primary diagnostic tool for CPAP initiation. This shift is driven by the demand for faster, more accessible, and advanced testing methods, ensuring patients can get their CPAP treatment sooner.

One of the key advantages of at-home testing is that it allows patients to sleep in their own beds, thereby reducing the sleep disruptions caused by unfamiliar surroundings, such as those in sleep clinics. Moreover, it is significantly more affordable, often costing a fraction of in-lab studies, and it bypasses long waitlists, allowing for quicker diagnosis. Furthermore, advancements in wearable technology now provide highly reliable data for identifying moderate-to-severe OSA. This transition in respiratory care from hospital settings to home environments has become a significant growth driver for CPAP adoption.

Additionally, health care systems prioritize reducing the inpatient costs and improve resource utilization, encouraging the use of home-based therapies. CPAP therapy aligns well with this model, as it does not require continuous clinical supervision once the patient is properly trained. Further, the development of portable CPAP devices has increased their adoption rates in rural populations. While in-lab studies remain necessary for complex cases like COPD and heart failure, HSAT has become the preferred, primary diagnostic tool for moderate-to-severe OSA diagnosis. Supported by favourable reimbursement policies and the shift toward home-based care, CPAP adoption is expanding rapidly, with home settings becoming the primary environment for long-term sleep apnea management.

To learn more about this report, download the PDF brochure

Device Type Segment Outlook

The continuous positive airway pressure market is categorized into automatic CPAP, fixed-pressure CPAP, and Bi-level PAP (BiPAP) devices. Automatic CPAP devices hold the largest share in the market due to their adaptive and technologically advanced features. The high demand for these devices is primarily driven by the shift towards personalized, home-based, and comfort-oriented therapy. Fixed pressure devices, although being the traditional/standard method of treatment for OSA, maintain a significant share in the market mostly due to their cost-effectiveness. However, Bi-level (BiPAP) devices are emerging as the fastest-growing segment. The demand for BiPAP devices is driven by their increasing adoption in complex respiratory care, the rising geriatric population, and the shift towards home healthcare.

Regional Outlook: Advanced sleep care infrastructure supports North America CPAP market leadership

North America holds the largest share of the global continuous positive airway pressure market, driven by increasing prevalence of breathing disorders, advanced sleep healthcare infrastructure, and widespread adoption of home sleep testing. The region also benefits from the presence of strong key players and favourable reimbursement policies. Followed by North America, Europe represents the second-largest market, with a stable growth supported by aging demographics, rising awareness of sleep disorders, advanced sleep labs, and supportive reimbursement policies. However, the Asia-Pacific is expected to witness the highest growth rate over the forecast period, due to rapid urbanization, increasing awareness, improving access to diagnostic services, and rising healthcare expenditure in the region.

Competitive Landscape Analysis

The global continuous positive airway pressure market is marked by the presence of established and emerging market players such as ResMed (US); Koninklijke Philips N.V. (Netherlands); Fisher & Paykel Healthcare Limited (New Zealand); React Health (3B Medical) (US); Transcend, Inc. (Somnetics International, Inc.) (US); Wellell Inc. (Apex Medical) (Taiwan); BMC; Armstrong Medical (Eakin Healthcare) (Ireland); Breas Medical AB (Sweden); Sefam Medical Ltd (France); Löwenstein Medical SE & Co. KG (Germany); and Trudell Healthcare Solutions Inc. (Vyaire Medical) (Canada) among others. Some of the key strategies adopted by market players include product innovation and development, strategic partnerships and collaborations, mergers and acquisitions, and geographic expansion.

Get a sample report for competitive landscape analysis

Organic and inorganic growth strategies adopted by players to establish their foothold in the market

Players operating in this market are adopting both organic and inorganic growth strategies, including technology partnerships, service expansions, and targeted acquisitions, to strengthen their capabilities, expand geographic presence, and enhance end-to-end offerings. For instance,

• In October 2025, ResMed announced the introduction of the AirTouch F30i, described as a full-face CPAP mask featuring a fabric cushion designed to provide comfort and support improved sleep health for people undergoing CPAP therapy
• In March 2025, Fisher & Paykel Healthcare announced the launch of the F&P Nova Nasal mask, developed to deliver comfort, stability, and performance for patients using CPAP therapy
• In June 2024, React Health announced the launch of IntelliPAP, an auto-adjusting PEEP option for its V*Home, V+Pro, V+C and VC+Pro ventilators, designed to automatically adjust PEEP levels in response to detected sleep-disordered breathing events, including obstructive sleep apnea, to support noninvasive ventilation therapy
• In October 2023, Fisher & Paykel Healthcare announced the launch of the F&P Solo mask, positioned as the world’s first AutoFit mask designed to simplify setup and improve the treatment experience for people with obstructive sleep apnea
• In March 2023, ResMed announced the acquisition of Somnoware, a provider of digital sleep and respiratory care diagnostics software, aiming to enhance its connected care ecosystem and strengthen its remote patient monitoring and diagnostic capabilities across CPAP and other respiratory therapy solutions

Report Scope

Global Continuous Positive Airway Pressure (CPAP) Market Segmentation

This report by Medi-Tech Insights provides the size of the global continuous positive airway pressure (CPAP) market at the regional- and country-level from 2024 to 2031. The report further segments the market based on device type, modality, and end-user.

Market Size & Forecast (2024-2031), By Device Type, USD Billion

• Automatic CPAP Devices
• Fixed Pressure CPAP Devices
• Bi-level PAP (BiPAP)

Market Size & Forecast (2024-2031), By Modality, USD Billion

• Standalone / Benchtop Systems
• Portable Devices

Market Size & Forecast (2024-2031), By End-user, USD Billion

• Hospitals
• Clinics
• Home-care Settings
• Others

Market Size & Forecast (2024-2031), By Region, USD Billion

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Rest of Asia Pacific
• Latin America
• Middle East & Africa

Related Reports

Sleep Apnea Devices Market Size, Segmented by Product (Therapeutic (PAP (CPAP, APAP, BPAP), Oral Appliances, Masks), Diagnostic (PSG, Home Sleep Testing, Oximeter), Age, Gender, End User (Sleep Clinics, Hospitals, Home Care Settings) & Regional Forecast to 2031

Global Sleep Apnea Oral Appliances Market Size & Trends Report Segmented by Product Type (Tongue Retaining and Mandibular Advancement Devices), Distribution Channels (Retail and Online Pharmacies), End-user (Hospitals, Homecare Settings) Forecast to 2031

Respiratory Care Devices Market (2026-2031) Size, Share, Analysis By Product (Respiratory Care Monitoring Devices, Diagnostics Respiratory Care Devices, Consumables and Accessories), Disease (Sleep Apnea, Asthma, Infectious Diseases), Region and Segment Forecast